Related Experiment Video

Updated: Aug 10, 2026

Platelet Adhesion and Aggregation Under Flow using Microfluidic Flow Cells
10:10

Platelet Adhesion and Aggregation Under Flow using Microfluidic Flow Cells

Published on: October 27, 2009

Platelet aggregation induced by arachidonic acid and thromboxane generation in patients with hypertension or

M Matsumoto, M Kusunoki, O Uyama

    Prostaglandins and Medicine
    |December 1, 1981
    PubMed

    Insights

    Platelet aggregation sensitivity to arachidonic acid (AA) was higher in hypertensive and cerebrovascular disease (CVD) patients. This finding suggests AA aggregability tests may help identify patients benefiting from aspirin therapy.

    Area of Science:

    • Cardiovascular Medicine
    • Hematology
    • Pharmacology

    Background:

    • Platelet aggregation plays a crucial role in thrombotic events associated with hypertension and cerebrovascular diseases (CVD).
    • Understanding platelet sensitivity to agonists like arachidonic acid (AA) is vital for assessing thrombotic risk.

    Purpose of the Study:

    • To investigate platelet aggregability in response to arachidonic acid (AA) in patients with essential hypertension and ischemic cerebrovascular diseases (CVD).
    • To explore the potential of AA-induced platelet aggregation as a biomarker for identifying patients who may benefit from anti-platelet therapy.

    Main Methods:

    • Platelet aggregability was assessed by determining the threshold concentrations of AA required to induce irreversible platelet aggregation.
    • Thromboxane B2 (TXB2) and prostaglandin H2 (PGH2) formation were studied in relation to AA-induced platelet aggregation.
    • Subjects included control individuals, patients with essential hypertension, and patients with CVD (both aspirin-naïve and aspirin-treated).

    Main Results:

    • Enhanced platelet sensitivity to AA was observed more frequently in patients with essential hypertension and/or CVD not taking aspirin compared to controls.
    • The study examined the relationship between AA-induced platelet aggregation and TXB2/PGH2 formation.

    Conclusions:

    • Assessment of platelet aggregability using AA may serve as a valuable tool for identifying patient subgroups who could benefit from secondary preventive treatments, such as aspirin.
    • The clinical utility of this aggregation test in managing patients already on aspirin therapy was also discussed.

    More Related Videos

    Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation09:13

    Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation

    Published on: April 6, 2017

    Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation04:37

    Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

    Published on: May 23, 2025

    Related Concept Videos

    Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

    Antihypertensive Drugs: Angiotensin II Receptor Blockers

    In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
    Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

    Anticoagulant Drugs: Low-Molecular-Weight Heparins

    Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
    Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

    Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

    Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
    Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
    Formation of the Platelet Plug01:22

    Formation of the Platelet Plug

    The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
    As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
    Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

    Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

    Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
    These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
    Peripheral Artery Disease I: Introduction01:30

    Peripheral Artery Disease I: Introduction

    Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...